Login to Your Account

Lee's inks alliance with Shenogen to develop checkpoint, TCM combo

By Pearl Liu
Staff Writer

Tuesday, November 28, 2017

HONG KONG – Hong Kong-based Lee's Pharmaceutical Holdings Ltd. has signed a co-development deal with Beijing Shenogen Pharma Group Ltd. to combine Lee's PD-L1 antibody with Shenogen's lead traditional Chinese medicine-derived small-molecule drug.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription